Welcome to BioSeeker Group!

Top 7 Cancer Indications - Therapeutic & Competitive Insights

Additional Information

Published Date Jan 1, 2007
Pages 750
PDF Fact Sheet View Fact Sheet for the report Top 7 Cancer Indications - Therapeutic & Competitive Insights in PDF
Format PDF
Publisher BioSeeker Group

Availability: In stock

$6,950.00

Quick Overview

With our 750 page report entitled "Top 7 Cancer Indications - Therapeutic & Competitive Insights" we present one of the largest reports published evaluating therapeutic and competitive insights in the anti-cancer arena.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Top 7 Cancer Indications - Therapeutic & Competitive Insights.

    To find out more about Top 7 Cancer Indications - Therapeutic & Competitive Insights, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Top 7 Cancer Indications - Therapeutic & Competitive Insights is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Executive Summary

With our 750 page report entitled "Top 7 Cancer Indications - Therapeutic & Competitive Insights" we present one of the largest reports published evaluating therapeutic and competitive insights in the anti-cancer arena. The report is structured according to the top 7 cancer indications: Breast cancer, Colon/colorectal cancer, Leukemia, Lung cancer, Lymphoma, Melanoma, and Prostate cancer.
No other report will provide a likewise structure and analysis. The report not only provides a close to complete structure of each cancer indication field, it as well describes the progress of hundreds of drugs in development. Information on most company related activities are included. More than 250 companies are involved in developing new drugs within the top seven cancer indications.

In the report BioSeeker does not only describe and analyze the latest years of progress but as we well provide an insight and framework to understand the complex field of cancer therapeutics. The report provides one of the most comprehensive coverage of the R&D trends to set the future marketplace. BioSeeker presents both an overview and a detailed description on the progress of key drugs in Phase II and III development, together with general descriptions on drugs and targets. In total we have selected more than 360 drug candidates to analyze. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in this market and current treatments will be changed for the benefit of more innovative therapies.

Scope of this report:

  • Progress analysis of Top 7 Cancer Indications, including players, drugs, clinical progress and pitfalls
                * Breast Cancer
                * Colon/colorectal cancer
                * Leukemia
                * Lung cancer
                * Lymphoma
                * Melanoma
                * Prostate Cancer
  • Includes more than 250 drug developing companies
  • Includes more than 360 candidate drugs
  • The report includes more than 160 Tables, 200 Boxes and 600 high quality references

Key reasons to read this report:

  • Understand the clinical and strategic challenges to the commercialization of drugs within the top 7 cancer indications
  • Assess opportunities and risks for the continued development of drugs in seven major cancer indications
  • Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development

1 EXECUTIVE SUMMARY

2 TABLE OF CONTENTS
21 LIST BOXES
22 LIST OF FIGURES
23 LIST TABLES

3 METHODOLOGY

4 LUNG CANCER

41 INTRODUCTION
411 Disease Definition
412 Etiology & Pathophysiology
413 Prognosis
414 Epidemiology

42 CURRENT TREATMENT STRATEGIES
421 Treatment Guide Lines

43 PROGRESS IN CURRENT TREATMENT STRATEGIES
431 Improvements adding microtubule inhibitor
432 Improvement of disease related symptoms in elderly patients
433 Toxicity profile favored
434 A new formula
435 Monotherapy?
436 Failed to demonstrate a survival advantage
437 Reduction in mortality risk

44 KEY DRUG STRATEGIES IN LUNG CANCER
441 Therapeutic Type, Targets & Mechanisms

45 COMPETITIVE LANDSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE
451 Grade 4 adverse events
452 No new remarks
453 No significant effect on overall survival
454 Bristol Myers Squibb entered into an agreement
455 Many uncertainties remain
456 Development terminated
457 Continuing Enrollment
458 Apoptotic inducer
459 Fully-human monoclonal antibody
4510 Eagerly awaiting data
4511 Mutations and response
4512 Statistically and clinically significant survival advantage
4513 Anti-idiotypic monoclonal antibody
4514 Shift in the development focus
4515 Sensitizer
4516 Treatment in earlier-stage cancer could be more effective
4517 Discontinued radiosensitizer
4518 Improvement in chemoradiotherapy
4519 Progress on HDAC inhibitor
4520 Progress Analysis Carboxyamidotriazole
4521 Chemotherapy naïve subjects

46 PROGRESS PROFILES ON APPROVED DRUGS
461 Docetaxel
462 Vinorelbine
463 Gemcitabine
464 Paclitaxel
465 Pemetrexed
466 Gefitinib
467 Erlotinib

5 COLON CANCER

51 INTRODUCTION
511 Epidemiology
512 Disease Definition
513 Prognosis for Colorectal Cancer by Stage

52 CURRENT TREATMENT STRATEGIES
521 Treatment Guide Lines

53 PROGRESS IN CURRENT TREATMENT STRATEGIES
531 A 50% Increase in Sales!
532 Topoisomerase inhibitor in First-line and Second-line Treatment
533 Fast Way to Approval
534 A Significant Reduction in the Risk of Death
535 Mice and Men
536 The Very Base

54 KEY DRUG STRATEGIES IN CRC
541 Therapeutic Type, Targets & Mechanisms
542 An Answer to Drug Resistance
543 Novel Therapies at the Gate
544 Tumor Vascularization & Antivascular Agents
545 Anti-angiogenesis: Therapeutic Strategies
546 Single Agent Therapy: Poorly Active in Advanced Tumors
547 Synergistic Effects with Cytotoxic Therapies
548 Vascular Targeting Agents
549 Vaccines
5410 Tumor antigens
5411 The Cell Vaccines Strategy
5412 Potent antigen presenting cells
5413 Emerging strategies
5414 Better-characterized antigens

55 COMPETITIVE LANDSCAPE IN CRC DRUG DEVELOPMENT
551 We are in the Lead
552 Amgen
553 Novartis and Schering
554 OSI, Genentech, Hoffmann La Roche & Pfizer
555 Sanofi-Aventis

56 CURRENT CRC DRUG DEVELOPMENT
561 Chemotherapy and Cytotoxic Drugs – A strategy reborn
562 Progress Analysis: CoFactor
563 Progress Analysis: Trabectedin (ET-743)
564 Progress Analysis: Pemetrexed
565 Progress Analysis: TS-1
566 Progress Analysis: Edotecarin
567 Progress Analysis: Aroplatin
568 Progress Analysis: Ixabepilone
569 EGF-R Inhibition and Other Signal Transduction Inhibitors
5610 Progress Analysis: Panitumumab
5611 Progress Analysis: Erlotinib (Tarceva)
5612 Progress Analysis: Gefitinib (Iressa)
5613 Progress Analysis: Pelitinib
5614 Progress Analysis: Sorafenib
5615 Signal Transduction Inhibitors in CRC
5616 Progress Analysis: BIO-117
5617 Progress Analysis: PD 0325901
5618 Antiangiogenetic- A team of players
5619 Progress Analysis: Vatalanib
5620 Progress Analysis: Thalidomide
5621 Progress Analysis: AMG 706
5622 Progress Analysis: Combretastatin A4 prodrug
5623 Progress Analysis: MBT 0206
5624 Progress Analysis: MEDI 522
5625 Progress Analysis: Tetrathiomolybdate
5626 Progress Analysis: WX-UK1
5627 COX-2 Inhibitors – What will become of us?
5628 Progress Analysis: P 54
5629 Progress Analysis: CV-247
5630 Apoptosis: An approach with a future
5631 Progress Analysis: HGS-ETR1
5632 Progress Analysis: APLIDIN
5633 Progress Analysis: VELCADE
5634 Progress Analysis: TELCYTA
5635 Progress Analysis EPO 906
5636 Progress Analysis: BIO-145
5637 Progress Analysis: Genasense
5638 Progress Analysis: Rexin-G
5639 Progress Analysis: Indisulam
5640 Progress Analysis: Seliciclib
5641 Progress Analysis: SYMADEX

57 NECROTIC CELL DEATH INDUCERS
571 Progress Analysis: RAV12
572 Progress Analysis: Cantuzumab mertansine
573 Progress Analysis: HuC242-DM4
574 Progress Analysis: COTARA

58 VACCINES: A HIGH THRESHOLD TO SUCCESS
581 Cell Vaccine
582 Progress Analysis: OncoVAX
583 Progress Analysis CANVAXIN
584 Progress analysis Collidem
585 Progress Analysis Dendricell
586 Progress Analysis: Neuvenge
587 Progress Analysis: Onyvax-CR
588 Progress Analysis: Ras-VAX
589 Vaccine: Direct Immunization with Protein and peptides
5810 Progress Analysis Avicine
5811 Progress Analysis: Oncophage
5812 Progress Analysis EP 2101
5813 Progress Analysis: MSI vaccine
5814 Progress Analysis: Corixa’s MUC-1 vaccine
5815 Progress Analysis: GV1002
5816 Anti-idiotype Monoclonal Antibodies
5817 Progress Analysis: CeaVac
5818 Progress Analysis: Onyvax-105
5819 DNA and Virally Encoded Vaccines
5820 Progress Analysis: TroVax
5821 Progress Analysis: ALVAC-CEA-B71
5822 Progress Analysis CEA-TRICOM
5823 Progress Analysis IR 705
5824 Progress analysis HYB-2055
5825 Passive Immunotherapy and Conjugated Antibodies
5826 Progress Analysis: IGN 101
5827 Progress Analysis: CEA-Cide
5828 Progress Analysis: LMB 9
5829 Progress Analysis: XR 303
5830 Progress Analysis ING-1

59 IMMUNO-MODULATORS
591 Progress Analysis: Dacogen
592 Progress Analysis: GCAN-101
593 Progress Analysis: ZYC300
594 Progress Analysis: Clofarabine

510 ONCOLYTIC VIROTHERAPY IN CRC – A TEAM OF FOUR
5101 Progress Analysis: OncoVEX
5102 Progress Analysis: Oncolytic HSV

6 PROSTATE CANCER
61 INTRODUCTION
611 Disease Definitions
612 Etiology & Pathophysiology
613 Epidemiology
614 Prognosis

62 CURRENT TREATMENT STRATEGIES
621 Localized Disease
622 Locally Advanced Prostate Cancer
623 Metastatic Prostate Cancer
624 Hormone-Sensitive Metastatic Prostate Cancer
625 Hormone-Refractory or Recurrent Metastatic Prostate Cancer

63 PROGRESS IN CURRENT TREATMENT STRATEGIES
631 Long-Term Follow-up Data not yet Been Published
632 Significant Reduced Risk of Distant Metastases
633 Adverse Events
634 No Difference in Overall Survival
635 Cross-over Design an Optimal Option?
636 Death due to Liver Failure
637 Survival Benefit
638 Subdermal Implant
639 No FDA Approval
6310 No Improvement in 5-year Disease-Free Survival
6311 Effective Secondary Hormonal Therapy?
6312 Synery in Combination

64 KEY THERAPEUTIC STRATEGIES FOR FUTURE THERAPIES
641 Therapeutic Type, Targets & Mechanisms

65 COMPETITIVE LANDSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE
651 Reduced Prostate Cancer Risk
652 High Activity in Metastatic AIPC Patients
653 Absence of Severe Toxicities
654 Waiting for Data
655 Probability of Regulatory Approval?
656 Co-development and License Agreement
657 Improves Predicted Survival?
658 Slow Progress & Development Partners
659 Exclusive License Agreement

66 CURRENT DRUG DEVELOPMENT: THE EARLY STAGE PIPELINE
661 New Data?
662 Terminated Study
663 More Than 50% PSA decline
664 Safety and Tolerability
665 Terminated?
666 Marker of Drug Effect
667 Preliminary Results for a Tyrosine Kinase Inhibitor
668 No Activity in Monotherapy
669 Dramatic Disappearance of Bone Metastatic Lesions
6610 PSA Response - Anthracycline

7 BREAST CANCER

71 INTRODUCTION
711 Clinical Practice Guidelines
712 Drugs approved by FDA

72 PROGRESS IN CURRENT TREATMENT STRATEGIES
721 A Hormone Therapeutic Losing Ground
722 Top Three Aromatase Inhibitors
723 Estrogen receptor downregulator
724 Side effects & resistance

73 COMPETITIVE LANDSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE
731 First in New Class of Protein-Bound Particle Drugs
732 High Efficacy and Reduced Cardiac Toxicity
733 A chemopotentiator
734 Microtubule-stabilizing agents
735 A Protein kinase inhibitor in Phase III
736 A bifunctional alkylating agent
737 Breast Cancer Trials That Did Not Meet Primary Endpoints

74 CURRENT DRUG DEVELOPMENT: THE EARLY STAGE PIPELINE
741 Keeping a low Profile
742 Protein Kinase Inhibitors a Future Treatment or Not?
743 Alimta
744 A Platinum Drug With Less Toxicity
745 A Proteasome Inhibitor on Track
746 Antisense: An Option for Breast Cancer or Not?
747 Two farnesyl transferase inhibitor making progress

75 APPENDIX B NEAR TERM "BREAST CANCER" PROGRESS
751 Progress profile Abraxane
752 Progress Profile Alimta
753 Progress Profile Arimidex
754 Progress Profile Aromasin
755 Progress Profile Avastin
756 Progress Profile BMS-217380-01
757 Progress Profile BMS-247550
758 Progress Profile CAELYX
759 Progress Profile CCI-779
7510 Progress Profile Faslodex
7511 Progress Profile Femara
7512 Progress Profile Fenretinide
7513 Progress Profile Gleevec
7514 Progress Profile GTI-2040
7515 Progress Profile Herceptin
7516 Progress Profile Iressa
7517 Progress Profile ISIS-2503
7518 Progress Profile Lapatinib
7519 Progress Profile Nolvadex
7520 Progress Profile Sarasar
7521 Progress Profile SDX-105
7522 Progress Profile Tarceva
7523 Progress Profile Theratope
7524 Progress Profile Velcade
7525 Progress Profile Zarnestra
7526 Progress Profile Zoladex
7527 Progress Profile ZD0473

8 MELANOMAS
81 INTRODUCTION
811 Etiology and Pathophysiology

82 CURRENT TREATMENT STRATEGIES

83 PROGRESS IN CURRENT TREATMENT STRATEGIES

84 CYTOTOXIC DRUGS
841 Dacarbazine
842 Cisplatin
843 Carboplatin
844 Carmustine
845 Melphalan
846 Paclitaxel
847 Tamoxifen
848 Temozolomide
849 Vinblastine/Vinorelbine

85 BIOLOGICAL TREATMENTS
851 Virulizin
852 Melacine
853 Alfanative (Multiferon)
854 Proleukin or (Macrolin)
855 Ceplene Maxamine

86 COMPETITIVE LANSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE
861 Phase I & II R&D Collaborations in Melanoma: Oxxon
862 Roche links Schering-Plough and Chugai Clusters Together – What Will the Outcome
Be?
863 GlaxoSmithKline Brings Wyeth, Hayashibara, Cytokinetics and Coley Pharmaceuticals
Together
864 GlaxoSmithKline and Sanofi-Aventis have a Joint Middle Man
865 R&D Collaboration Trends in Melanoma Projects

87 KEY THERAPY STRATEGIES
871 Therapeutic Type, Targets & Mechanisms

88 CURRENT DRUG DEVELOPMENT: THE EARLY STAGE PIPELINE
881 Vaccines: Active Immunotherapy a Benefit or Not?
882 Vaccine: Direct Immunization with Tumor Antigens
883 Progress Analysis: Oncophage
884 Progress Analysis: GMK
885 Progress Analysis: NOVOVAC-M1
886 Progress Analyses: SB 249553
887 Progress Analysis: MJV 101
888 Progress Analysis: A Russian Melanoma Vaccine
889 Progress Analysis: GV 1001
8810 Progress Analyses: Elea Vaccine
8811 Progress Analysis: NY-ESO-1 ISCOMS
8812 Progress Analysis: F 50040
8813 Progress Analysis: Transvax
8814 Vaccines: Is the Development of Cell Therapy Stalling?
8815 Progress Analysis: Canvaxin
8816 Progress Analysis: Dexosome
8817 Progress Analysis: M-VAX ORGINAL
8818 Progress Analysis: OncoVax
8819 Progress Analysis: Uvidem
8820 DNA Vaccine
8821 Progress Analysis: Alvac-Mage1/Mage3
8822 Progress Analysis: Oxxon Vaccine
8823 Progress Analysis: Therion’s Melanoma Vaccine
8824 Progress Analysis: ImmunoVex trimelan
8825 Progress Analysis: OncoVEXGM-CSF
8826 Progress Analysis: GVAX
8827 Progress Analysis: Gp100 + MART-1
8828 Progress Analysis: MAGE-3-TK OR M3TK
8829 Optimism for New Vaccine Adjuvants
8830 Progress Analysis: Enhanzyn
8831 Progress Analysis: QS-21
8832 Progress Analysis: Zadaxin
8833 Progress Analysis: Mobista
8834 Progress Analysis: ProMune
8835 Progress Analysis: Talabostat
8836 Immunostimulants: The Push in Passive Immunotherapy
8837 Immuno-Biologicals: The Work Horse
8838 Progress Analysis: MDX-010
8839 Progress Analysis: Peginterferon alfa-2b
8840 Progress Analysis: Iboctadekin
8841 Progress Analysis: BAY 504798
8842 Progression Analysis: EMD 273063
8843 Progress Analysis: Urocidin
8844 Progress Analysis: CP-675206
8845 Immunostimulation by Gene Therapy
8846 Progress Analysis: ALLOVECTIN-7
8847 Inovio Biomedical Corporation and Lee Moffitt Cancer Center Make a Joint move in
Melanoma Gene therapy
8848 Progress Analysis: TG 1041
8849 One Small Molecular Drug Candidate
8850 Progress Analysis: Lenalidomide
8851 Antiangiogenesis- The Major Research Focus for the Next Decade?
8852 Progress Analysis: Sorafenib
8853 Progress Analysis: Vitaxin
8854 Progress Analysis: Avastin
8855 Progress Analysis: Endostatin
8856 Progress Analysis: PI 88
8857 Apoptosis Inducers: Moving into Market
8858 Progress Analysis: Genasense
8859 Progress Analysis: Didemnin B
8860 Progress Analysis: INGN 241
8861 Progress Analysis: KOS 953
8862 Small Molecules Inhibiting Cell Growth Faces Difficulties
8863 Progress Analysis: Temozolomide
8864 Progress Analysis: Pivanex
8865 Progress Analysis: Karenitecin
8866 Progress Analysis: Lomeguatrib
8867 Progress Analysis: PD 0325901
8868 Progress Analysis: SB 715992
8869 Progress Analysis: INO 1001
8870 Progress Analysis: CP 4055
8871 Other Biological Drugs
8872 Progress Analysis: AP 12009
8873 Progress Analysis: Ecromeximab
8874 Progress Analysis: ILX 651
8875 Progress Analysis: Kahalalide F
8876 Progress Analysis: ABX MA1

9 THE LYMPHOMAS
91 INTRODUCTION
911 Disease Definition
912 Etiology & Pathophysiology
913 Epidemiology
914 Prognosis
915 Hodgkin’s Disease
9151 Cellular Classification
9152 Stage Information
916 Non-Hodgkin
9161 Cellular Classification
9162 Stage Information

92 CURRENT TREATMENT STRATEGIES
921 Hodgkin’s Disease
922 Radiation Therapy
923 Chemotherapy
924 Transplantation
925 Treatment Option Overview
926 Non-Hodgkin’s Lymphoma
927 Radiation Therapy
928 Chemotherapy
929 Immunotherapy
9210 Bone Marrow and Peripheral Blood Transplants
9211 Watch and Wait
9212 Treatment Option Overview

93 PROGRESS IN CURRENT TREATMENT STRATEGIES
931 Hodgkin
932 Non-Hodgkin
933 Rituxan
934 Bexxar
935 Zevalin

94 KEY THERAPEUTIC STRATEGIES FOR FUTURE TREATMENTS
941 Therapy Type, Targets & Mechanisms

95 COMPETITIVE LANDSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE
951 Continous Development?
952 A Pivotal Trial
953 FDA Consider Granting Conditional Approval
954 CR Rate of 85%
955 No Longer Pursue Development
956 FDA Fast Track Designation
957 Long-Term Follow Up
958 Prodrug Approved
959 Just Small Studies
9510 Worldwide License
9511 87 Percent Overall Improvement
9512 Ongoing Data
9513 More Mabs
9514 Significant Clinical Activity

96 CURRENT DRUG DEVELOPMENT: THE EARLY STAGE PIPELINE
961 Prolonged Stabilization in a Subset
962 Antibody Conkugate
963 Need Combinations
964 Selective PKC Inhibitor
965 No Grade 4 Toxicity
966 More Antibodies

10 THE LEUKEMIAS
101 INTRODUCTION
1011 Disease Definitions
10111 The Lymphoid Malignancies
10112 The Myeloid Malignancies
1012 Etiology & Pathophysiology
10121 The Lymphoid Malignancies
10122 The Myeloid Malignancies
1013 Epidemiology
1014 Prognosis
10141 The Lymphoid Malignancies
10142 The Myeloid Malignancies

102 CURRENT TREATMENT STRATEGIES
1021 The Lymphoid Malignancies
1022 The Myeloid Malignancies

103 PROGRESS IN CURRENT TREATMENT STRATEGIES
1031 The Lymphoid Malignancies
1032 The Myeloid Malignancies

104 KEY THERAPEUTIC STRATEGIES FOR FUTURE THERAPIES
1041 Therapeutic Type, Targets & Mechanisms

105 COMPETITIVE LANDSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE
1051 The Lymphoid Malignancies
1052 Minimal Toxicity in Elderly Patients
1053 Increased Risk for Febrile Neutropenia
1054 No Conclusive Data
1055 The Myeloid Malignancies
1056 Development on Hold
1057 Long-Term Follow-up Data
1058 No Improvement in Statistically Significant Overall Response
1059 Approval First Half 2006
10510 New Data?
10511 Two New Phase III by Novartis

106 CURRENT DRUG DEVELOPMENT: THE EARLY STAGE PIPELINE
1061 The Myeloid Malignancies
1062 Flt3-ligand Inhibitors
1063 PKC Inhibitor With Less Toxicity?
1064 Still Under Development?
1065 Codevelopment Schering and Novartis
1066 Reduction in Costs
1067 Discontinue Clinical Trial
1068 Combination of Lonafarnib and Imatinib
1069 Effots in Antimetabolite Development
10610 Protease Inhibitor in 117 Abstracts
10611 Immunostimulant
10612 No new information
10613 The Lymphoid Malignancies
10614 Phosphodiesterase Inhibitor Seeking Partner
10615 Slow Progress
10616 Minor Responses

107 DRUGS APPROVED FOR THE TREATMENT OF LEUKEMIA: A HISTORICAL PERSPECTIVE

11 DISCLAIMER
111 LIABILITY
112 COMPLETENESS

12 DRUG INDEX

13 COMPANY INDEX

21 List Boxes
Box 1: Quick facts on Docetaxel
Box 2: Scientific Data on Docetaxel
Box 3: Scientific Data on Vinorelbine
Box 4: Quick Facts – Vinorelbine
Box 5: Quick Facts – Gemcitabine
Box 6: Scientific Data on Gemcitabine
Box 7: Scientific Data on Pemetrexed
Box 8: Quick Facts – pemetrexed
Box 9: Quick Facts – Gefitinib
Box 10: Scientific Data on Gefitinib
Box 11: Quick Facts – Erlotinib
Box 12:Example of Observed Efficacy in preclinical models
Box 13: Anti-angiogenesis: Therapeutic strategies
Box 14: Anti-angiogenesis: Problems that has to be solved
Box 15: Mechanisms which tumor cells use to evade an immune reaction
Box 16: Quick Facts – ANX-510
Box 17: Quick Facts - Trabectedin
Box 18: Quick Facts - Pemetrexed
Box 19: Quick Facts – TS-1
Box 20: Quick Facts – Edotecarin
Box 21: Quick Facts – Aroplatin
Box 22: Quick Facts - Ixabepilone
Box 23: Quick Facts – Panitumumab
Box 24: Quick Facts – Erlotinib
Box 25: Scientific Data on Erlotinib
Box 26: Quick Facts – Gefitinib
Box 27: Scientific Data on Gefitinib
Box 28: Quick Facts – Pelitinib
Box 29: Quick Facts – Sorafenib
Box 30: Quick Facts – BIO-117
Box 31: Quick Facts – PD 0325901
Box 32: Quick Facts - Vatalanib
Box 33: Quick Facts - Thalomide
Box 34: Quick Facts – AMG 706
Box 35: Quick Facts - Combretastatin
Box 36: Quick Facts – MBT 0206
Box 37: Quick Facts – MEDI 522
Box 38: Quick Facts - Tetrathiomolybdate
Box 39: Quick Facts – WX-UK1
Box 40: Quick Facts – P 54
Box 41: Quick Facts – CV-247
Box 42: Targets for Apoptosis Directed Therapy
Box 43: Selection of Patents Relating to Apoptosis
Box 44: Quick Facts - HGS-ETR1
Box 45: Quick Facts - APLIDIN
Box 46: Quick Facts - VELCADE
Box 47: Millennium’s License Agreement with Ortho Biotech
Box 48: Quick Facts - TELCYTA
Box 49: Quick Facts - EPO 906
Box 50: Quick Facts – BIO-145
Box 51: Quick Facts - Genasense
Box 52: Quick Facts - Rexin-G
Box 53: Quick Facts - Indisulam
Box 54: Quick Facts - Seliciclib
Box 55: Quick Facts - SYMANDEX 1
Box 56: Quick Facts - RAV12
Box 57: Quick Facts - Cantuzumab mertansine
Box 58: Quick Facts - HuC242-DM4
Box 59: Quick Facts - Cotara
Box 60: Quick Facts - OncoVAX
Box 61: Quick Facts - Canvaxin
Box 62: Quick Facts - Collidem
Box 63: Quick Facts - Dendricell
Box 64: Quick Facts - Neuvenge
Box 65: Quick Facts – Onyvax-CR
Box 66: Quick Facts - Ras-VAX
Box 67: Quick Facts - Avicine
Box 68: Quick Facts - Oncophage
Box 69: Quick Facts – EP 2101
Box 70: Quick Facts – MSI Vaccine
Box 71: Quick Facts – MUC-vaccine
Box 72: Quick Facts - OncoVAX
Box 73: Quick Facts - CeaVac
Box 74: Quick Facts - Onyvax-105
Box 75: Quick Facts - TroVax
Box 76: Quick Facts – ALVA-CEA-B71
Box 77: Quick Facts – CEA-TRICOM
Box 78: Quick Facts – IR 705
Box 79 Quick Facts - Amplivax
Box 80: Quick Facts – IGN 101
Box 81: Quick Facts – CEA-Cide
Box 82: Quick Facts - LMB 9
Box 83: Quick Facts - KSB 303
Box 84: Quick Facts – ING-1
Box 85: Quick Facts -Dacogen
Box 86: Quick Facts – GCAN-101
Box 87: Quick Facts - ZYC300
Box 88: Quick Facts - Clofarabine
Box 89: Quick Facts - OncoVEX
Box 90: Quick Facts – NV 1020
Box 91: The Eastern Cooperative Oncology Group Study
Box 92: Southwest Oncology Group Study 99-16 Design
Box 93: TAX 327 Study Design
Box 94: Quick Facts - Toremifene
Box 95: Quick Facts - Bevacizumab
Box 96: Quick Facts - Genasense
Box 97: Quick Facts - R-flurbiprofen
Box 98: Quick Facts - Provenge
Box 99: Quick Facts - Satraplatin
Box 100: Quick Facts - GVAX
Box 101: Quick Facts - Exisulind
Box 102: Quick Facts - Vapreotide
Box 103: Quick Facts - DCVax
Box 104: Mechanisms which tumor cells use to evade an immune reaction
Box 105: Introgen’s INGN 241 Shows Vaccine Properties
Box 106: Quick Facts - Oncophage
Box 107: Oncophage - Designation and Status
Box 108: Quick Facts - GM2-KLH Vaccine
Box 109 Progenics reaquires rights to vaccine
Box 110: Completed Melanoma Phase III trials
Box 111: Quick Facts - NovaVac-M1
Box 112: Quick Facts - SB 249553
Box 113: Quick Facts - MJV 101
Box 114: Quick Facts - Russian Melanoma Vaccine
Box 115: Quick Facts - GV 1001
Box 116: Quick Facts - N-Acetyl-GM3 ganglioside
Box 117: Quick Facts: neu-glycolyl-GM3 ganglioside
Box 118: Quick Facts - NY-ESO-1 ISCOMS
Box 119 NY-ESO-1 and ISCOMATRIX
Box 120: Quick Facts - F 50040
Box 121: KpOmpA technology
Box 122: Quick Facts - TransVax
Box 123: Quick Facts - Canvaxin
Box 124: Canvaxin - Designation and Status
Box 125: CancerVax Milestone payment
Box 126: Quick Facts - Dexosome
Box 127: Important Milestones and License Fees
Box 128: Quick Facts - M-VAX
Box 129: Quick Facts -OncoVax
Box 130: Quick Facts - Uvidem
Box 131: Agreements Between Sanofi-Aventis and IDM
Box 132: Quick Facts - Alvac-Mage1/Mage3
Box 133: Quick Facts - Oxxon vaccine
Box 134: Quick Facts - Therion’s Melanoma Vaccine
Box 135: Quick Facts - ImmunoVEX trimelan
Box 136: Quick Facts - OncoVEX GM-CSF
Box 137: Quick Facts - GVAX 4
Box 138: Agreement Japan Tobacco and Cell Genesys
Box 139: Predicted launch of GVAX
Box 140: Quick Facts - Gp100 + MART-1 vaccine
Box 141: Quick Facts - MAGE-3-TK
Box 142: Quick Facts - Enhanzyn
Box 143: Quick Facts - QS-21
Box 144: Quick Facts - ZADAXIN
Box 145: Quick Facts - Mobista
Box 146: Quick Facts - ProMune
Box 147: Quick Facts - Talabostat
Box 148: Quick Facts – MDX-010
Box 149: Quick Facts – Peginterferon alfa-2b
Box 150:Quick Facts – BAY-504798
Box 151: Quick Facts – EMD-273063
Box 152: Quick Facts - Urocidin
Box 153:Quick Facts – CP-675206
Box 154: Quick Facts – ALLOVECTIN-7
Box 155: Quick Facts – Cytokine, Gene therapy
Box 156: Quick Facts – TG 1041
Box 157: Quick Facts - Lenalidomide
Box 158: Introgen’s INGN 241 Shows Anti-angiogenesis Properties
Box 159: Quick Facts - Sorefenib
Box 160: Quick Facts - Vitaxin
Box 161: Quick Facts Bevacizumab
Box 162: Quick Facts - Endostatin
Box 163: Quick Facts – PI88
Box 164: Quick Facts - Oblimersen
Box 165: Quick Facts – Didemnin B
Box 166: Quick Facts – INGN 241
Box 167: Recent Identification of Molecular Pathways Underlying Activity of Introgen’s INGN 241
Anti-Cancer Therapy
Box 168: Quick Facts – KOS 953
Box 169: Quick Facts - Temozomide
Box 170: Molecular Pathways Underlying the Activity of Temozolomide’s Anti-Cancer Therapy
Box 171: Quick Facts - Pivanex
Box 172: Quick Facts - Karenitecin
Box 173: Quick Facts - Lomeguatrib
Box 174: Quick Facts – PD 0325901
Box 175: Quick Facts – SB 715992
Box 176: Quick Facts – INO 1001
Box 177: Quick Facts – CP 4055
Box 178: Quick Facts – AP 12009
Box 179: Quick Facts - Ecromeximab
Box 180: Quick Facts – ILX 651
Box 181: Quick Facts – Kahalalide F
Box 182: Quick Facts – ABX MA1
Box 183: Updated REAL/WHO Classification for B-Cell Neoplasms
Box 184: Subclassification of Stage
Box 185: Updated REAL/WHO Classification for B-Cell Neoplasms
Box 186: Updated REAL/WHO Classification for T-Cell and Putative NK-Cell Neoplasms
Box 187: Staging Subclassification System
Box 188: Possible Complications of Treatment
Box 189 Study Details
Box 190: Major Treatment Regimes
Box 191: CLL Staging System
Box 192: Quick Facts - Clofarabine
Box 193: Quick Facts – Alemtuzumab
Box 194: Quick Facts - Gemtuzumab
Box 195: Quick Facts - Imatinib
Box 196: Quick Facts - Rituximab
Box 197: Quick Facts - Genasense
Box 198: Quick Facts - Flavopiridol
Box 199: Quick Facts - Atra
Box 200: Quick Facts - Gvax
Box 201: Quick Facts - Zarnestra
Box 202: Quick Facts – BAY 43-9006
Box 203: Quick Facts - Ceplene
Box 204: Quick Facts - Valspodar
Box 205: Quick Facts - CEP-701
Box 206: Quick Facts - PKC412
Box 207: Quick Facts - SU5416
Box 208: Quick Facts - PTK787
Box 209: Quick Facts - Cloretazine
Box 210: Company Statement on Progress
Box 211: Quick Facts - Troxacitabine
Box 212: Quick Facts - FK228
Box 213: Quick Facts - Decitabine
Box 214: Quick Facts - VELCADE
Box 215: Velcade Sales 2005
Box 216: Quick Facts - AG-858
Box 217: Quick Facts - Avastin
Box 218: Quick Facts - OSI-461
Box 219: Quick Facts - Xcytrin
Box 220: Quick Facts - AP23573

22 List of Figures
Figure 1: Summarized Description of Colon Cancer Development and Clinical Outcome
Figure 2 Oxxon’s R&D Collaborations in Melanoma
Figure 3 Schering Plough’s R&D Collaborations in Melanoma
Figure 4 GlaxoSmithKline and Wyeth’s R&D Collaborations in Melanoma
Figure 5 Bristol-Myers Squibb’s and Sanofi-Aventis’ Collaborations in Melanoma
Figure 6: Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways

23 List Tables
Table 1: Chemotherapeutic drugs for treatment of NSCLC
Table 2 Near Term Approved Drugs for the Treatment of NSCLC
Table 3: Chemotherapy Drugs off Patent
Table 4 Generalized Illustration Depicting the Key Elements Involved in the Apoptotic Pathways
Table 5 VTA agents under development
Table 6 EGFR or VEGFR inhibitors
Table 7: FMS-like tyrosine kinases and their Synonyms
Table 8: Fms-related Tyrosine Kinase Targets in Development
Table 9: Protein Kinase Targets in Clinical Trials for Lung Cancer
Table 10 Cancer immunotherapy strategies
Table 11 Recently presented studies Lapatinib
Table 12 Recently presented studies ZD-6474
Table 13 Recently presented studies vinflunine
Table 14 Recently presented studies Panitumumab
Table 15 Recently presented studies Genasense
Table 16 Recently presented studies cetuximab
Table 17 Recently presented studies bevacizumab
Table 18 Recently presented studies bexarotene
Table 19 Recently presented studies Xcytrin
Table 20: 5-year Survival Rate in CRC
Table 21: Risk Factors for Colon Cancer Development
Table 22: Summary of Colorectal Cancer Regimens
Table 23: Summary of Chemotherapy Drugs
Table 24: Capecitabine - Major Developmental Milestones
Table 25: Ironotecan - Major Developmental Milestones
Table 26: Bevacizumab - Major Developmental Milestones
Table 27: Sales Predictions on Bevacizumab
Table 28: Oxaliplatin – Major Developmental Milestones
Table 29: Cetuximab – Major Developmental Milestones
Table 30: Sales Predictions on Cetuximab
Table 31: Common Gene/Protein Defects in Apoptotic Pathways
Table 32: A Selection of Apoptosis Targets in Development
Table 33: Selection of VTA agents under clinical development as cancer therapeutics
Table 34: Colorectal Cancer Vaccines in Development
Table 35: The Representation of Investigators in the CRC Drug Pipeline
Table 36: Drugs with Four or more Investigators
Table 37: Phase III Competitors
Table 38: Industrial Investigators with the Highest Number of CRC Drugs in Phase I to Phase III
development
Table 39: Phase I –Phase III Chemotherapy and Cytotoxic Drugs in Development
Table 40: Phase I-Phase III EGF-R Inhibitors as CRC Therapeutics
Table 41: Phase I-Phase III Signal Transduction Inhibitors in CRC
Table 42: Phase I – Phase III Antiangiogenic Drugs in Development
Table 43: Current COX-2 Inhibitors in Development
Table 44: Apoptotic Cell Death Inducers in Development
Table 45: Necrotic Cell Death Inducers in Development
Table 46 Cell therapy based platform in pipeline as potential treatment of colorectal cancer
Table 47: Protein/peptide vaccine as potential treatment of colorectal cancer
Table 48: Anti-idiotype monoclonal antibodies
Table 49: Nucleic acid and virally encoded vaccines
Table 50: Monoclonal Antibodies
Table 51: Immuno-modulators in CRC
Table 52: The TNM System
Table 53: Lifestyle factors
Table 54: Historical Summary of Clinical Studies on Patients with Late Stage Disease
Table 55: Short Facts Abarelix
Table 56: Short Facts Bicalutamide
Table 57: Short Facts Carboplatin
Table 58: Short Facts Docetaxel
Table 59: Short Facts Mitoxantrone
Table 60: Short Facts Flutamide
Table 61: Short Facts Goserelin
Table 62: Short Facts Histrelin
Table 63: Short Facts Lanreotide
Table 64: Short Facts Leuprolide
Table 65: Short Facts Nilutamide
Table 66: Short Facts Estramustine
Table 67: Summary of Recent Clinical Studies on Patients with Late Stage Disease
Table 68: Ongoing Late Stage Clinical Studies
Table 69: Cancer Immunotherapy Strategies
Table 70: Near Term Progress Toremifene
Table 71: Near Term Progress Bevacizumab
Table 72: Near Term Progress Oblimersen
Table 73: Near Term Progress R-flurbiprofen
Table 74: Near Term Progress APC8015
Table 75: Near Term Progress Satraplatin
Table 76: Near Term Progress GVAX
Table 77: Near Term Progress Exisulind
Table 78: Summary of Prostate Cancer Late Stage Pipeline
Table 79: Paclitaxel
Table 80: Epothilone
Table 81: Ixabepilone
Table 82: PTK/ZK
Table 83: Arsenic trioxide
Table 84: Retinoic Acid
Table 85: Imatinib
Table 86: Bortezomib
Table 87: Sorafenib
Table 88: Doxorubicin
Table 89: Summary of Prostate Cancer Early Stage Pipeline
Table 90: Summary of Mid-Stage to Late stage Investigational Agents Under Development for the
Treatment of Breast Cancer
Table 91: Critical Risk Factors for Development of Melanoma
Table 92: Definition and Description of Stages of Melanoma
Table 93: Prognosis of the 4 Stages of Malignant Melanoma
Table 94: Current Cytotoxic Drugs for Treatment of Melanoma
Table 95: Development Milestones- Virulizin
Table 96: Development Milestones - Melacine
Table 97: Development Milestones - Alfanative
Table 98: Development Milestones - Proleukin
Table 99: Number of Collaborations and Drugs per Developmental Stage
Table 100: Deployed Strategies for Blocking Angiogenesis
Table 101: Tumor antigen
Table 102: In vivo gene therapy
Table 103: Cell therapy based platform in pipeline as potential treatment of melanoma
Table 104: Ex vivo gene therapy loading of antigen presenting cells
Table 105: Overview of Immunostimulants in Development based on Type
Table 106: Overview of Immuno-Biologicals
Table 107: MDX-010’s Collaborative History and Landscape
Table 108: Overview of Gene Therapy Drugs for Immunostimulation
Table 109: Anti-angiogenisis Drugs under Development
Table 110:Selected Regulatory Progress of Sorafenib
Table 111: Overview Apoptopic Inducer Drugs
Table 112: Selected Regulatory Progress of Didemin B
Table 113: Overview of Small Molecule Drugs
Table 114: Overview of Various Biological Drugs in Development for Melanoma
Table 115: Drugs Used in the Treatment of Lymphoma
Table 116 Summary of Strategies Enhancing Antibody Function
Table 117 Cancer Immunotherapy Strategies
Table 118: Protein Kinase Targets in Clinical Trials for Lymphoma
Table 119: Near Term Progress Aldesleukin
Table 120: Near Term Progress Arsenic trioxide
Table 121: Near Term Progress BiovaxID
Table 122: Near Term Progress Bortezomib
Table 123: Near Term Progress Epratuzumab
Table 124: Near Term Progress FavId
Table 125: Near Term Progress MyVax
Table 126: Near Term Progress Nelarabine
Table 127: Near Term Progress Genasense
Table 128: Near Term Progress Pixantrone
Table 129: Near Term Progress Temsirolimus
Table 130: Near Term Progress Zanolimumab
Table 131: Near Term Progress Flavopirido
Table 132: Near Term Progress Bevacizumab
Table 133: Near Term Progress CMC-544
Table 134: Near Term Progress Galiximab
Table 135: Near Term Progress LY317615
Table 136: Near Term Progress SGN-40
Table 137: Near Term Progress Apolizumab
Table 138: Near Term Progress SGN-30
Table 139: ALL Classification
Table 140: Latest Approved Drugs for the Treatment of Leukemia
Table 141: Kinase Inhibitors in Development for the Treatment of Leukemia
Table 142: Near Term Progress Rituximab
Table 143: Near Term Progress Oblimersen
Table 144: Near Term Progress Alvocidib
Table 145: Near Term Progress ATRA
Table 146: Near term progress GVAX
Table 147: Near tearm progress HuM195
Table 148: Near term progress Zarnestra
Table 149: Near Term Progress Sorafenib
Table 150: Near Term Progress Valspodar
Table 151: Summary of Current Late Stage Pipeline
Table 152: Near term progress CEP-701
Table 153: Near Term Progress PKC412
Table 154: Near Term Progress SU5416
Table 155: Near Term Progress PTK787
Table 156: Near Term Progress VNP40101M
Table 157: Near Term Progress Troxacitabine
Table 158: Near Term Progress Decitabine
Table 159 Near Term Progress Bortezomib
Table 160 Near Term Progress AG-858
Table 161: Near Term Progress Bevacizumab
Table 162: Near Term Progress OSI-461
Table 163: Near Term Progress Xcytrin
Table 164: Near Term Progress AP23573
Table 165: Summary of Current Early Stage Pipeline

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Top 7 Cancer Indications - Therapeutic & Competitive Insights.
    To find out more about Top 7 Cancer Indications - Therapeutic & Competitive Insights, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Top 7 Cancer Indications - Therapeutic & Competitive Insights is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Oncology' category:


Hematological Cancers - A Therapeutic & Competitive Insight
BioSeeker Group has studied the progress of 125 of the most prominent drugs in development for the treatment of hematological cancers. This extensive 190+ pages report not only describes and analyzes the latest years of progress in lymphoma and leukemia, it also provides an insight and framework to understand this complex field. Learn More


Triple Analysis: Lung Cancer, Pancreatic Cancer and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Lung Cancer, Pancreatic Cancer and Prostate Cancer. Learn More